VRTX241227C405000
- 1.70
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Wall Street Today: Market Turns Around, Let's See if it Lasts
Live Stock News: Monday Market Falling, 'Too Big to Fail' Earnings to Start Q1 Report Season
Jefferies Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Vertex Pharmaceuticals: Strong Future Potential With Key Drug Launches and Underappreciated Opportunities
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $494
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Citi Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know
Weekly Buzz: CES Came and Brought the Pain? That's Unexpected
Wall Street Today: Labor Gains Hurt a Hurting Market
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
First Earnings Show Beats are Back, December Jobs Climbed but Market Falls Friday | Live Stock
Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Incorporated (VRTX) Slid Due to Setbacks In Clinical Trials